Zhou Shijie, Bagga Amit
Schulich School of Medicine & Dentistry, Western University, Windsor, ON, Canada.
Windsor Regional Hospital, ON, Canada.
Can J Kidney Health Dis. 2020 Oct 22;7:2054358120951371. doi: 10.1177/2054358120951371. eCollection 2020.
Terbinafine is an antimicrobial agent commonly prescribed for fungal infections. Its side effect profile is generally benign, but there is limited evidence that it has the potential to cause rhabdomyolysis. Rhabdomyolysis is a potentially life-threatening condition caused by profound muscle injury. It has characteristic findings of muscle pain, weakness, and dark urine. When recognized early, patients with rhabdomyolysis can be managed conservatively with hydration and watchful monitoring. However, if treatments are delayed, or in severe cases of rhabdomyolysis, complications such as electrolyte abnormalities, acute kidney injury, and disseminated intravascular coagulation can develop.
A previously healthy 22-year-old male presented with nausea, vomiting, and dark urine after taking terbinafine 250 mg daily for a tinea infection for 9 days. He developed severe rhabdomyolysis with a serum creatine kinase (CK) of >100 000 U/L as well as anuric acute kidney injury.
The clinical history combined with the diagnostic findings suggest acute kidney injury and rhabdomyolysis associated with terbinafine use.
Terbinafine use was stopped immediately. The patient was started on intravenous fluids and bicarbonate drip. Hemodialysis was initiated to prevent further complications. After his CK level decreased and his clinical status stabilized, he was discharged home and continued to receive outpatient hemodialysis treatments.
The patient's kidney function returned to baseline after 1 month of outpatient hemodialysis treatments.
In this report, we present a case of rhabdomyolysis associated with terbinafine use that progressed to acute kidney injury requiring dialysis. Our case highlights a less known and severe side effect of this medication and emphasizes the importance of early recognition and treatment of rhabdomyolysis.
特比萘芬是一种常用于治疗真菌感染的抗菌药物。其副作用通常较为轻微,但有有限的证据表明它有可能导致横纹肌溶解。横纹肌溶解是一种由严重肌肉损伤引起的潜在危及生命的病症。它具有肌肉疼痛、无力和深色尿液等特征性表现。如果早期识别,横纹肌溶解患者可通过补液和密切监测进行保守治疗。然而,如果治疗延迟,或者在横纹肌溶解的严重病例中,可能会出现电解质异常、急性肾损伤和弥散性血管内凝血等并发症。
一名先前健康的22岁男性在每日服用250毫克特比萘芬治疗体癣9天后出现恶心、呕吐和深色尿液。他发生了严重的横纹肌溶解,血清肌酸激酶(CK)>100000 U/L,以及无尿性急性肾损伤。
临床病史结合诊断结果提示与特比萘芬使用相关的急性肾损伤和横纹肌溶解。
立即停用特比萘芬。患者开始接受静脉输液和碳酸氢盐滴注。开始进行血液透析以预防进一步的并发症。在他的CK水平下降且临床状况稳定后,他出院回家并继续接受门诊血液透析治疗。
经过1个月的门诊血液透析治疗后,患者的肾功能恢复到基线水平。
在本报告中,我们呈现了一例与特比萘芬使用相关的横纹肌溶解病例,该病例进展为需要透析的急性肾损伤。我们的病例突出了这种药物一种鲜为人知且严重的副作用,并强调了早期识别和治疗横纹肌溶解的重要性。